» Articles » PMID: 18366345

Evidence for Direct CFTR Inhibition by CFTR(inh)-172 Based on Arg347 Mutagenesis

Overview
Journal Biochem J
Specialty Biochemistry
Date 2008 Mar 28
PMID 18366345
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

CFTR (cystic fibrosis transmembrane conductance regulator) is an epithelial Cl- channel inhibited with high affinity and selectivity by the thiazolidinone compound CFTR(inh)-172. In the present study, we provide evidence that CFTR(inh)-172 acts directly on the CFTR. We introduced mutations in amino acid residues of the sixth transmembrane helix of the CFTR protein, a domain that has an important role in the formation of the channel pore. Basic and hydrophilic amino acids at positions 334-352 were replaced with alanine residues and the sensitivity to CFTR(inh)-172 was assessed using functional assays. We found that an arginine-to-alanine change at position 347 reduced the inhibitory potency of CFTR(inh)-172 by 20-30-fold. Mutagenesis of Arg347 to other amino acids also decreased the inhibitory potency, with aspartate producing near total loss of CFTR(inh)-172 activity. The results of the present study provide evidence that CFTR(inh)-172 interacts directly with CFTR, and that Arg347 is important for the interaction.

Citing Articles

Global functional genomics reveals GRK5 as a cystic fibrosis therapeutic target synergistic with current modulators.

Botelho H, Lopes-Pacheco M, Pinto M, Railean V, Pankonien I, Caleiro M iScience. 2025; 28(3):111942.

PMID: 40040803 PMC: 11876911. DOI: 10.1016/j.isci.2025.111942.


Allosteric inhibition of CFTR gating by CFTRinh-172 binding in the pore.

Gao X, Yeh H, Yang Z, Fan C, Jiang F, Howard R Nat Commun. 2024; 15(1):6668.

PMID: 39107303 PMC: 11303713. DOI: 10.1038/s41467-024-50641-1.


Structural basis for CFTR inhibition by CFTR-172.

Young P, Levring J, Fiedorczuk K, Blanchard S, Chen J Proc Natl Acad Sci U S A. 2024; 121(10):e2316675121.

PMID: 38422021 PMC: 10927578. DOI: 10.1073/pnas.2316675121.


Putting bicarbonate on the spot: pharmacological insights for CFTR correction in the airway epithelium.

Zajac M, Lepissier A, Dreano E, Chevalier B, Hatton A, Kelly-Aubert M Front Pharmacol. 2023; 14:1293578.

PMID: 38149052 PMC: 10750368. DOI: 10.3389/fphar.2023.1293578.


An ex vivo rat trachea model reveals abnormal airway physiology and a gland secretion defect in cystic fibrosis.

Harris E, Easter M, Ren J, Krick S, Barnes J, Rowe S PLoS One. 2023; 18(10):e0293367.

PMID: 37874846 PMC: 10597513. DOI: 10.1371/journal.pone.0293367.